Development and validation of liquid chromatography-tandem mass spectrometry method to quantify dasatinib in plasma and its application to a pharmacokinetic study
DOI:
https://doi.org/10.1590/s2175-97902023e21415Keywords:
Paullinia cupana, Caffeine, Guarana extract, High Performance Liquid Chromatography.Abstract
Dasatinib, a potent oral multi-targeted kinase inhibitor against Src and Bcr-Abl, can decrease inflammatory response in sepsis. A simple and cost-effective method for determination of an effective dose dasatinib was established. This method was validated in human plasma, with the aim of reducing the number of animals used, thus, avoiding ethical problems. Dasatinib and internal standard lopinavir were extracted from 180 uL of plasma using liquid-liquid extraction with methyl tert-butil ether, followed by liquid chromatography coupled to triple quadrupole mass spectrometry in multiple reaction monitoring mode. For the pharmacokinetic study, 1 mg/kg of dasatinib was administered to mice with and without sepsis. The method was linear over the concentration range of 1-98 ng/mL for DAS in mice and human plasma, with r2>0.99 and presented intra- and interday precision within the range of 2.3 - 6.2 and 4.3 - 7.0%, respectively. Further intra- and interday accuracy was within the range of 88.2 - 105.8 and 90.6 - 101.7%, respectively. The mice with sepsis showed AUC0-t = 2076.06 h*ng/mL and Cmax =102.73 ng/mL and mice without sepsis presented AUC0-t = 2128.46 h*ng/mL. Cmax = 164.5 ng/mL. The described analytical method was successfully employed in pharmacokinetic study of DAS in mice.
Downloads
References
Agência Nacional de Vigilância Sanitária (Brasil). Resolução RDC nº. 27, de 17 de maio de 2012. Requisitos mínimos para a validação de métodos bioanalíticos empregados em estudos com fins de registro e pós-registro de medicamentos.
Andriamanana I, Gana I, Duretz B, Hulin A. Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorefenib, sunitinib and vandetanib in human plasma using LC/MS/MS. J Chromatogr B. 2013;926:83-91.
Berton G, Mocsai A, Lowell CA. Src and Syk kinases: key regulators of phagocytic cell activation. Trends Immunol. 2005;26(4):208-214.
Birch M, Morgan PE, Handley S, Ho A, Ireland R, Flanagan RJ. Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib. Biomed Chromatogr. 2013;27(3):335-342.
Bouchet S, Chauzit E, Ducint D, Castaing N., Canal-Raffin M, Moore N, et al. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clin Chim Acta. 2011;412(11-12):1060-1067.
Cao SF, Wang XM, Zheng LC, Sun M, Wang YF, Fan RT. Development of a LC-MS/MS Method for the determination of dasatinib in rat plasma. Lat Am J Pharm. 2015;24(3):542-546.
Fraser CK, Lousberg EL, Kumar R, Hughes TP, Diener KR, Hayball JD. Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo. Exp Hematol. 2009;37(12):1435-1444.
Furlong MT, Agrawal S, Hawthorne D, Lago M, Unger S, Krueger L, et al. A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: Application to a clinical pharmacokinetic study. J Pharm Biomed Anal. 2012;58:130-135.
Futosi K, Nemeth T, Pick R, Vantus T, Walzog B, Mocsai A. Dasatinib inhibits proinflammatory functions of mature human neutrophils. Blood. 2012;119(21):4981-4991.
Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013;41(5):1167-1174.
Gonçalves-de-Albuquerque CF, Rohwedder I, Silva AR, Ferreira AS, Kurz ARM, Cougoule C, et al. The Yin and Yang of tyrosine kinase inhibition during experimental polymicrobial sepsis. Front Immunol. 2018;30(9):901.
Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA, et al. Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B. 2009;877(22):1982-1996.
Hsieh Y, Galviz G, Zhou Q, Duncan C. Hydrophilic interaction liquid chromatography/tandem mass spectrometry for simultaneous determination of dasatinib, imatinib and nilotinib in mouse plasma. Rapid Commun. Mass Spectrom. 2009;23(9):1364-1370.
Huynh HH, Pressiat C, Sauvageon H, Madelaine I, Maslanka P, Lebbé C, et al. Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS. Ther Drug Monit. 2017;39(1):43-54.
Jacobson B-M, Olsson A, Fakt C, Öhman D. The use of human plasma as matrix for calibration standards in pre-clinical LC-MS/MS methods-A way to reduce animal use. J Pharm Biomed Anal . 2011;54(4):826-829.
Kamath AV, Wang J, Lee FY, Marathe PH. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-yargeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol. 2008;61(3):365-376.
Kovács M, Németh T, Jakus Z, Sitaru C, Simon E, Futosi K, et al. The Src family kinases Hck, Fgr, and Lyn are critical for the generation of the in vivo inflammatory environment without a direct role in leukocyte recruitment. J Exp Med. 2014;211(10):1993-2011.
Kralj E, Trontelj J, Pajic T, Kristl A. Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry. J Chromatogr B. 2012;903:150-156.
Lankheet NAG, Hillibrand MJX, Rosing H, Schellens JHM, Beijnen JH, Huitema ADR. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinob, sorafenib and sunitib in human plasma by liquid chromatography coupled with tandem mass spectrometry. Biomed Chromatogr . 2013;27(4):466-76.
Li W, Jian W, Fu Y. Basic Sample Preparation Techniques in LC-MS bioanalysis - protein precipitation, liquid- liquid extraction, and solid-phase extraction. In: Sample Preparation in LC-MS Bioanalysis. 1st ed. John Wiley & Sons, Inc. 2019:3-30.
Lowe DB, Bose A, Taylor JL, Tawbi H, Lin Y, Kirkwood JM, et al. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology. 2014;3(1):e27589.
Luo FR, Yang Z, Camuso A, Smykla R, McGlinchey K, Fager K, et al. Dasatinib (BMS-354825) Pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res. 2006;12(23):7180-7186.
Maher HM, Alzoman NZ, Shehata SM, Abanmy NO. Validated UPLC-MS/MS method for the quantification of dasatinib in plasma: Application to pharmacokinetic interaction studies with nutraceuticals in Wistar rats. PLoS One. 2018;13(6):e0199208.
McPherson VA, Sharma N, Everingham S, Smith J, Zhu HH, Feng GS, et al. SH2 domain-containing phosphatase-2 protein-tyrosine phosphatase promotes Fc epsilon RI-induced activation of Fyn and Erk pathways leading to TNF alpha release from bone marrow-derived mast cells. J Immunol. 2009;183(8):4940-4947.
Mičová K, Friedecký D, Faber E, Adam T. Isotope dilution direct injection mass spectrometry method for determination of four tyrosine kinase inhibitors in human plasma. Talanta. 2012;93:307-313.
Mócsai A, Walzog B, Lowell CA. Intracellular signaling during neutrophil recruitment. Cardiovasc Res. 2015;107(3):373-85.
Munford RS. Severe sepsis and septic shock: the role of gram-negative bacteremia. Annu Rev Pathol. 2006;1(1):467-496.
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention, Division of Healthcare Quality Promotion (DHQP) CDC Data and Reports, 2016. Available at: Available at: https://www.cdc.gov/sepsis/datareports/index.html Accessed May 25, 2020.
» https://www.cdc.gov/sepsis/datareports/index.html
Okutani D, Lodyga M, Han B, Liu M. Src protein tyrosine kinase family and acute inflammatory responses. Am J Physiol Lung Cell Mol Physiol. 2006;291(2):L129-141.
Patel PN, Samanthula G, Sridhar V, Arla R, Varanasi KKVS, Kumar VVS. Validated LC-MS/MS method for simultaneous determination of Dasatinib and Stagliptin in rat plasma and this application to pharmacokinetic study. Anal Methods. 2014;6(2):433-439.
Rabenau KE, Dolan M, Yohe S, Ustu C. Effectiveness of dasatinib in accelerated-phase chronic myeloid leukemia with p190 BCR-ABL1 and a second Philadelphia chromosome. Cancer genetics. 2014;207(3):109-110.
Roche S, McMahon G, Clynes M, Connor RO. Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib. J Chromatogr B. 2009;877(31):3982-3990.
Van Erp NP, de Wit D, Guchelaar H, Gelderblom H, Hessing TJ, den Hartigh J. A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B. 2013;937:33-43.
Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007;7(5):345-356.
Wen C, Zhang Q, He Y, Deng M, Wang X, Ma J. Gradient elution LC-MS determination of dasatinib in rat plasma and its pharmacokinet study. Acta Chromatogr. 2015;27(1):81-91.
Zeng J, Cai HL, Jiang ZP, Wang Q, Zhu Y, Xu P, et al. A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma. J Pharm Anal. 2017;7(6):374-380.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
